Patient participation

From Wikipedia, the free encyclopedia
  (Redirected from Participatory medicine)
Jump to navigation Jump to search

Patient participation is a trend that arose in answer to perceived physician paternalism. However, only rarely can unchecked physician paternalism be justified, and unlimited patient autonomy would presumably be equally abhorrent.[1]

In recent years, the term "patient participation" has been used in many different contexts. These include, for example: participatory medicine,[2] health consumerism,[3] and patient-centered care.[4][a] For the latter context, i.e. patient-centered care, a more nuanced definition was proposed in 2009 by the president of the Institute for Healthcare Improvement Donald Berwick: "The experience (to the extent the informed, individual patient desires it) of transparency, individualization, recognition, respect, dignity, and choice in all matters, without exception, related to one's person, circumstances, and relationships in health care"[6] are concepts closely related to patient participation. In the UK over the course of 2016 two new relevant terms have expanded in usage: Patient and Public Involvement (PPI) and Engagement (PPIE)[7] in the sense of the older term coproduction (public services).

Patient participation is a generic term, and thus no list can be exhaustive; nonetheless, the following description shall subdivide it into several areas where patients and/or their advocates have a role.[8]

Formation of health policy as stakeholders[edit]

Patient participation, as it pertains to the formation of health policy, is a process that involves patients as stakeholders, advisors and shared decision makers. The practice of engaging patients in health policy originated from the consumer advocacy movement, which prioritized consumer safety, access to information and public participation in public health programs.[9] Depending on the context, patient participation in health policy can refer to informed decision making, health advocacy, program development, policy implementation, and evaluation of services.[9] Patient participation in health policy can affect many different levels of the health care system. Hospitalized individuals may participate in their own medical care in an effort to make shared decisions. In other areas, patients act as advocates by serving as members of organizational and governmental policy committees.

Increased patient participation in health policy can lead to improvements in patient satisfaction, quality and safety, cost savings and population health outcomes.[9][10] Involving patient participation in health policy research can also ensure that public health needs are accurately incorporated into policy proposals.[11] When solicited for participation by policymakers and industry leaders, patients can influence health policy, and both groups benefit from collaboration on goal setting and outcome measurement. By providing feedback in the form of survey responses, patients give community health officials and hospital leaders helpful feedback on the perceived quality and accessibility of health care services. Furthermore, patient satisfaction scores from these surveys have become an important metric by which hospitals are evaluated and compared to one another.

Patient participation has driven the development of a variety of health policies, ranging from the expansion of hospital visitation hours to the implementation of patient-centered bedside rounding by hospital medical teams. Patient participation has contributed to improvements in the nurse-to-nurse handoff process by engaging with staff to discuss change-of-shift information at the patient's bedside. Patient participation in care coordination has also lead to the utilization of electronic medical records that patients can access and edit.[10] By engaging with patients and patient advocacy groups, policymakers can support patients to shape public policy. Examples include facilitation of public participation in research, town hall meetings, public information sessions, internet and mobile-based surveys and open comment periods on proposed legislation. Hospitals promote patient participation by empowering patients to serve as advisers and decision makers, including on quality improvement teams, patient safety committees, and family-centered care councils. Similarly, foundations, nonprofit organizations, and government agencies can create funding mechanisms requiring and supporting patient participation in societal decisions and priority setting. Clinicians, delivery systems, and policy makers cannot assume that patients have certain capabilities, interests, or goals, nor can they dictate the pathway to achieving a patient's goals.[10]

In health technology assessment[edit]

Patient participation in health technology assessment (HTA) is an approach to HTA which aims to include patients in the process of HTA. It is sometimes called consumer or patient engagement or consumer or patient involvement, although in HTA the latter term has been defined to include research into patients' needs, preferences and experiences as well as participation per se.[12] In HTA, patient participation is also often used to include the participation of patient groups, patient advocates, and patients' families and carers in the process.[13]

As HTA aims to help healthcare funders, such as governments, make decisions about health policy, it often involves the question as to whether to use broadly defined health "technologies", and if so, how and when; then patients comprise a key stakeholder in the HTA process. Additionally, because HTA seeks to assess if a heath technology produces useful outcomes for patients in real world settings (clinical effectiveness) that are good value for money (cost effectiveness), understanding patients' needs, preferences and experiences is essential.[14]

When patients take part in HTA, their knowledge gained from living with a condition and using treatments and services can add value to an HTA.[15] Sometimes they are called experience-based experts or lay experts.[16] Patients can add value to HTAs by providing real world insights (e.g. implications of benefits and side effects, variation in clinical practice)[17] highlighting outcomes that matter, addressing gaps and uncertainties in the published literature,[18][19] and contributing to the value construct that shapes assessments and decisions.[16]

Approaches[edit]

In 2017, a book was published on patient involvement in HTA (Eds Facey KM, Hansen HP, Single ANV) bringing together research, approaches, methods and case studies prepared by 80 authors.[20] It demonstrates that practices vary between HTA bodies, and patients can potentially contribute at every stage of an HTA from scoping the questions asked about the health technology, providing input, interpreting the evidence, and drafting and communicating recommendations. It suggests that patient participation in HTA depends on two-way communication and is a dialogue for shared learning and problem solving. The approach taken should be driven by the goal of participation.[21] The most common way that patients take part in HTA is by providing written submissions and participating in expert meetings (for example as an equal member of an expert group or by attending an expert meeting to present information and answer questions).[22]

Limitations and criticism[edit]

Although patient participation has been adopted and developed by a variety of HTA bodies around the world, there are limitations and criticisms of its use. These include concern about how and when to involve patients,[23] the burden of participation for patients, representativeness of patients, the potential for conflict of interest (in relation to patient groups receiving funding from manufacturers), and lack of evaluation of patient participation.[24] Facey et al. (2017) published the book on patient involvement in HTA to establish consistent terminology in the field and demonstrate a range of recognised approaches and methods found in published literature. Authors also highlighted the challenges of evaluation, rapid (short HTAs) and the problem of HTA bodies confusing patient input (information provided by patients and patient groups taking part in HTA) with patient-based evidence (robust research into patients' needs, preferences and experiences). The book itself is not open access, but the lead editor also published a paper on the topic six years before the larger collection.[25] One of the issues for patient participation in HTA is that HTA has often been constructed as a scientific process which must remain free from the subjective input of patients. Likewise, Gauvin et al. report that their "analysis reveals that HTA agencies' role as bridges or boundary organizations situated at the frontier of research and policymaking causes the agencies to struggle with the idea of public involvement" (page 1518).[26]

However, HTA would be better understood as a policy tool which critically reviews scientific evidence for a local context and this review is shaped by those involved in the process.[27] There are many ways that public participation in HTA, including patients, can be implemented. In fact, an entire "typology of issues" has been developed by Gauvin et al., in which each type is "related to the most appropriate public involvement methods". Facey (2017) built on this work in Chapter 5 to describe it in detail for patient participation in HTA.

Sociologist Andrew Webster sees the problem as "a failure to recognise that evaluation is a contested terrain involving different sorts of evidence related to different sorts of context (such as the experimental derived from clinical trials, evidential, derived from existing clinical practice, and experiential, based on patients' experiences of an intervention".[28]

A further issue for patient participation in HTA is that of the individual versus the group. The HTAi's list available for endorsement on values for patient involvement express this issue as 'involvement ... contributes to equity by seeking to understand the diverse needs of patients with a particular health issue, balanced against the requirements of a health system that seeks to distribute resources fairly amongst all users'.[29]

Kelly et al. explain (with their original citations shown here in brackets): "From the moment Archie Cochrane linked questions of clinical effectiveness to cost effectiveness [17] and cost utility analysis was chosen as the basis for assessing value for money, [Evidence-Based Medicine] EBM and HTA have been framed within the utilitarian philosophical tradition. Utilitarianism is premised on the view that actions are good insofar as they maximize benefit for the greatest number [51]. This is not necessarily congruent with what is in the best interest of an individual patient [34]."[30]

Transatlantic rise of health advocacy[edit]

Workshops in Denmark and Austria have resulted in calls to action to reinforce patients' role in SDM and health advocacy. The Danish workshop recommended the new Toolbox of resources for patient participation from the European Patients' Academy on Therapeutic Innovation (EUPATI).[31][32] Furthermore the Danish workshop reported that the European Medicines Agency would be "measuring the impact of patient involvement", this being crucial to establishing credibility.[33] And indeed, measurement is provided for in the place cited.[34]

In Austria, a bibliography inter alia resulted from the most recent event in a workshop series continuing through 2019 entitled "Toward a Shared Culture of Health: Enriching and Charting the Patient-Clinician Relationship held from 10–16 March 2017.[35]

In the Netherlands, there is a debate about the relative value of patient participation versus decisions without explicitly empowering patients. Bovenkamp is one of the most vocal opponents challenging patients as stakeholders in clinical guideline development.[36] Adonis is more positive in her shorter paper.[37] Caron-Flinterman goes into more detail in her dissertation.[38] She is cited in a more recent open-access survey laying out researchers' various views, especially on the ethical dimensions of engaging patients as partners within research teams.[39]

In Norway, Nilsen et al. were critical of patients' role in health policy and clinical guideline development in their Cochrane Intervention Review.[40] Two other Norwegian researchers, though, in unison with the workshop findings above, expand the list of areas where patients' views matter: "The central arena for patient participation is the meeting between patient and health professional, but other important areas of involvement include decisions at the system and policy levels".[41]

In the United States there are several trends emerging with potential international implications: Health 2.0, artificial intelligence in healthcare (AI), the role of entrepreneurs, the value of patient participation in precision medicine and mobile health or MHealth, which will be dealt with in greater detail below.

In shared decision making and artificial intelligence[edit]

Prior to the recent advances in technology, patient participation was limited to shared decision making (SDM), a form of participation that occurred specifically between a patient and their physician in clinical practice, but can be regarded as a step forward.[42] Changes in modern technology now allow computers to play an increasingly important role in healthcare decision making. Examples of artificial intelligence (AI) technology that is being used in healthcare include IBM's Watson Health, which is intended to assist in the diagnosis and treatment of difficult illnesses or disease.[43] One of the Watson's objectives is to highlighting findings developed by Watson's computing skills and access to everyday information and give concrete suggestions that are tailored to the expertise of the physician, type of ailment, and needed level of care. Physicians can use ailment specific programs such as the Watson for Oncology app, which is aimed at the detection and treatment of tumors. Artificial intelligence is being used more frequently in patient participatory healthcare.

Role of entrepreneurship[edit]

Entrepreneurs have led the challenge to conventional health thinking since Craig Venter took on the NIH with the 1000 Genomes Project in 2008. Mike Milken, another entrepreneur and stock trader, founded the Santa Monica, California based Milken Institute. Following the institute's inception, Milken launched the Fastercures program, which "brings together patient advocates, researchers, investors and policymakers from every sector of the medical research and development system to eliminate the roadblocks that get in the way of a faster cure". The Fastercures program proposes patient-center improvements and advancements in the modern healthcare arena.[44]

In 2010, the U.S. Government boosted patient participation by launching its own Patient-Centered Outcomes Research Institute. PCORI is striving to systematize its evaluation metrics to prove where results show improvement. PCORI was created by provisions in the Patient Protection and Affordable Care Act of 2010. The 501(c) organization has faced a great deal of scrutiny over funding, specifically when it was revealed PCORI was funded by a new tax originating from the Affordable Care Act.[45]

Precision medicine[edit]

Four years after the spectacular 1000 Genomes Project hoped to call in a new era of precision medicine (PM), some opinion leaders have spoken up for reassessing the value of patient participation to be seen as a driver of PM. The Chancellor of the University of California, San Francisco, for instance, wrote an editorial in Science Translational Medicine calling for an amendment to the social contract to boost patient participation, citing a historical precedent: "We need only look back to the human immunodeficiency virus (HIV)/AIDS epidemic during the 1980s to experience the power of patient advocacy combined with the dogged pursuit of scientific discovery and translation; clearly, motivated patients and scientists as well as their advocates can influence political, scientific, and regulatory agendas to drive advances in health."[46]

In 2011 a seminal[peacock term] paper on the topic came out written by Hood and Friend.[47]

A second success story is that of the patient John W. Walsh, who founded Alphanet, which has funnelled tens of millions of dollars into research on chronic obstructive pulmonary disease or COPD.[48]

A more ethically ambivalent development involving patient-funded research involves so-called named patient programs and expanded access.

In Health 2.0[edit]

Taking its name from the "Web 2.0" label given to describe the social-networking emphasis of the Internet since 2004,[49] Health 2.0 is the use of web and social networking technologies to facilitate patient and physician interaction and engagement, usually through an online web platform or mobile application.[50] Health 2.0 is sometimes used interchangeably with the term "Medicine 2.0," however, both terms refer to a personalized health care experience that aims to increase collaboration between patients and providers, while increasing patient participation in their own health care.[51] In addition to increased patient-physician interactions, Health 2.0 platforms seek to educate and empower patients through increased accessibility of their own health care information, such as lab reports or diagnoses.[49] Some Health 2.0 platforms are also designed with remote medicine or telemedicine in mind, such as Hello Health.[52] The advent of this communication method between patients and their medical providers is thought to change the way medicine is delivered,[49] evidenced by a growing focus on innovating health technology, such as the annual Health 2.0 conference.[53] One way Health 2.0 technologies can increase patient participation by actively engaging patients with their doctors is through the use of electronic health records, which are electronic versions of a physician's after-visit summaries.[54] Electronic health records can also include the ability for patients to communicate to their physicians electronically for scheduling appointments or reaching out with questions. Other ways electronic health records can enhance patient participation include electronic health records that alert physicians to potentially dangerous drug interactions,[55] reducing time to review a patient's medical history in an emergency situation,[56] enhanced ability for managing chronic conditions like hypertension,[55] and reducing costs through increased medical practice efficiency.[57]

Mobile health (MHealth)[edit]

MHealth is bringing promising solutions to meet the growing demand for care. With more and more evidence suggesting that the most effective treatment models involve specialized, multi-faceted approaches, and require a variety of materials and effort on both the physician's and patient's end.[58] Mobile applications serve as both a method for increasing health literacy, and as a bridge for patient-physician communication (thus increasing patient participation).[59] There are a broad number of ways to increase participation through the use of web-based and mobile applications. Live videoconferencing appointments have proven effective, especially in the field of mental health, and can be especially significant in providing services to low resource, rural communities.[60] Patient reminders have increased patient participation in attending preventative screenings, and it is possible that similar reminders distributed automatically via web-based applications, such as patient portals, have the potential to provide similar benefits at a potentially lower cost.[61]

To meet this demand for materials, production of patient-centered health applications is occurring at a rapid pace, with estimates of over 100,000 mobile applications available for use already.[59] This boom in production has led to a developing concern regarding the amount of research and testing the application undergoes before going live, while others see promise in patient's having greater access to treatment materials.[59] Some of that concern includes whether or not the patient will continue to use the mobile application specific for their treatment needs over time.[59]

Patients as research stakeholders[edit]

Patient participation can include a broad spectrum of activities for human subjects during clinical trials and has become associated with several other words such as "patient engagement" or "decision making".[62]

This includes agenda-setting, clinical guideline development and clinical trial design.

Clinical trials[edit]

In the US, trends in patient participation have been influenced by a variety of sources and previous political movements. One such source for patient participation in clinical research was the AIDS epidemic in the 1980s and 1990s. During the epidemic, the AIDS activists argued not only for new clinical trial models, but for the importance of additional social service groups to support a wider range of potential human subjects.[63] Since then, the FDA has taken several steps to include patients earlier in the drug development process. The authorization of Prescription Drug User Fee Act (PDUFA) V in 2012 included the Patient-Focused Drug Development (PFDD) initiative to provide the FDA with a way of hearing the patients' perspectives and concerns.[64] Similarly, the European Medicine Agency (EMA) has been attempting to incorporate patient perspectives during the evaluation of medicinal products by the EMA scientific committees.[65]

There has been an increased interest among healthcare providers, such as nurses, in cultivating patient participation.[66] Due to this increased interest, studies have been done to assess the benefits and risks of patient participation and engagement in research. For benefits, patient engagement improves patient outcomes as well as clinical trial enrollment and retention.[67] For risks, it has been proposed that the inclusion of patient participation may lead to extended research times and increased funding for clinical trials.[67]

Two of the reasons to cultivate patient participation in clinical research have been the growth of patient organizations along with the development of databases and the concept of a patient or disease registry.[68] Computer databases allow for the mass collection and dissemination of data. Registries, specifically, not only allow patients to access personal information but also allow physicians to review the outcomes and experiences of multiple patients who have received treatment with medicinal products .[69][70] Furthermore, registries and patient participation have been particularly important to the development of rare-disease medicines. In the US, the Rare Diseases Clinical Research Network (RDCRN) was created in 2003 which includes a registry for patients afflicted with a rare-disease.[71][72] This registry provides information to the patients and allows physicians to contact potential patients for enrollment in clinical trials.[72] "Patient registry" is a developing term, and this 2013 open-access book provides a comprehensive description of the trend toward registries and their networks, i.e. the "broader research collaboratives that connect individual registries".[73]

Patients have a new resource to help them navigate the clinical trials landscape and find lay summaries of mediTal research in the OpenTrials database launched by the AllTrials campaign in 2016 as part of open data in medicine.[74]

Precision medicine will change the conduct of clinical trials, and thus the role of patients as subjects. "Key to making precision medicine mainstream is the ongoing shift in the relationship between patients and physicians" comments N.J. Schork from the Venter Institute in Nature. He cites as reasons for this development a growing interest in 'omics' assays and cheap and efficient devices that collect health data.[75]

A newer article in Nature outlines the conditions with which patent participation can be optimized, and it is co-authored by Jennifer Wagner et al.[76]

With cancer being a prime target for precision medicine, Dr. Jennifer Carter, founder of the start-up N-of-One, recruits patients to "participate" in clinical trials to help find a cure for it.[77]

See also[edit]

Notes[edit]

  1. ^ Patient-centered care especially has been subject to reinterpretation since 2001, when the Institute of Medicine (IOM) defined patient-centered care as "providing care that is respectful of and responsive to individual patient preferences, needs, and values and ensuring that patient values guide all clinical decisions."[5]

References[edit]

  1. ^ Cohn, Felicia (February 2004). "Addressing Paternalism with Patients' Rights: Unintended Consequences". Virtual Mentor. 6 (2). doi:10.1001/virtualmentor.2004.6.2.pfor1-0402. 
  2. ^ Dyson, Esther (21 October 2009). "Why Participatory Medicine?". Journal of Participatory Medicine. 1 (1): e1. ISSN 2152-7202.  open access publication – free to read
  3. ^ Robinson, James C. (December 2005). "Managed Consumerism In Health Care". Health Affairs. 24 (6): 1478–89. doi:10.1377/hlthaff.24.6.1478Freely accessible. ISSN 0278-2715. PMID 16284020. 
  4. ^ "Declaration on: Patient-Centered Healthcare" (PDF). International Alliance of Patients' Organizations. 2016. Retrieved 30 June 2016. 
  5. ^ Institute of Medicine (2001). "Executive Summary". Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press. p. 6. doi:10.17226/10027Freely accessible. ISBN 978-0-309-07280-9 – via National Academies Press. 
  6. ^ Berwick, Donald M. (July 2009). "What Patient-Centered Should Mean: Confessions of an Extremist". Health Affairs. 28 (4): w555–65. doi:10.1377/hlthaff.28.4.w555Freely accessible. PMID 19454528. Retrieved 19 July 2016. 
  7. ^ "Is 2017 the year for PPIE?". National Institute for Health Research. National Health Service. 23 February 2017. Retrieved 19 June 2017. 
  8. ^ Kelty, C; Panofsky, A; Currie, M; Crooks, R; Erickson, S; Garcia, P; Wartenbe, M; Wood, S (2015). "Seven dimensions of contemporary participation disentangled". Journal of the Association for Information Science and Technology. 66: 474–488. doi:10.1002/asi.23202. Retrieved May 12, 2017. 
  9. ^ a b c Souliotis, Kyriakos; Agapidaki, Eirini; Peppou, Lily Evangelia (September 2017). "Assessing Patient Organization Participation in Health Policy: A Comparative Study in France and Italy" (PDF). International Journal of Health Policy Management. 6(x): 1–11. 
  10. ^ a b c Carman, Kristin L.; Dardess, Pam; Maurer, Maureen; Sofaer, Shoshanna; Adams, Karen; Bechtel, Christine; Sweeney, Jennifer (2013-02-01). "Patient And Family Engagement: A Framework For Understanding The Elements And Developing Interventions And Policies". Health Affairs. 32 (2): 223–231. doi:10.1377/hlthaff.2012.1133. ISSN 0278-2715. PMID 23381514. 
  11. ^ Souliotis, Kyriakos; Agapidaki, Eirini; Peppou, Lily Evangelia; Tzavara, Chara; Samoutis, George; Theodorou, Mamas (2016-08-01). "Assessing Patient Participation in Health Policy Decision-Making in Cyprus". International Journal of Health Policy and Management. 5 (8): 461–466. doi:10.15171/ijhpm.2016.78. 
  12. ^ Facey, Karen; Boivin, Antoine; Gracia, Javier; Hansen, Helle P; Los Scalzo, Alessandra.; Mossman, Jean; Single, Ann (2010). "Patients' perspectives in HTA: A route to robust evidence and fair deliberation". International Journal of Technology Assessment in Health Care. 26: 334e340. doi:10.1017/S0266462310000395. 
  13. ^ Hailey, David; Werkö, Sophie; Bakri, Rugayah; Cameron, Alun; Göhlen, Britta; Myles, Susan; Pwu, Jasmine; Yothasamut, Jomkwan (2013). "Involvement of consumers in health technology assessment activities by INAHTA agencies". International Journal of Technology Assessment in Health Care. 29: 79–83. doi:10.1017/S026646231200075X. 
  14. ^ Facey, Karen; Boivin, Antoine; Gracia, Javier; Hansen, Helle P; Los Scalzo, Alessandra.; Mossman, Jean; Single, Ann (2010). "Patients' perspectives in HTA: A route to robust evidence and fair deliberation". International Journal of Technology Assessment in Health Care. 26: 334–340. doi:10.1017/S0266462310000395. 
  15. ^ Berglas, Sarah; Jutai, Lauren; MacKean, Gail; Weeks, Laura (2016). "Patients' perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review".  (Open Access)
  16. ^ a b Lopes, Edilene; Street, Jackie; Carter, Drew; Merlin, Tracy (2015). "Involving patients in health technology funding decisions: stakeholder perspectives on processes used in Australia". doi:10.1111/hex.12356. PMC 5055264Freely accessible.  (Open Access)
  17. ^ Health Equality Europe (HEE). "Understanding Health Technology Assessment (HTA)" (PDF). 
  18. ^ Menon, Devidas; Stafinski, Tania; Dunn, A; Short, H (2015). "Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: A rare opportunity?". Patient. 8: 29–39. doi:10.1007/s40271-014-0106-8. 
  19. ^ Berglas, Sarah; Jutai, Lauren; MacKean, Gail; Weeks, Laura (2016). "Patients' perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review".  (Open Access)
  20. ^ Facey, Karen; Ploug Hansen, Helle; Single, Ann (eds.). Patient Involvement in Health Technology Assessment. Springer. 
  21. ^ Abelson, Julia; Boesveld, Sarah E; Li, Kathy K (2015). "Supporting quality public and patient engagement in health system organizations: Development and usability testing of the Public and Patient Engagement Evaluation Tool". Health expectations. 19: 817–27. doi:10.1111/hex.12378. PMC 5152717Freely accessible. PMID 26113295.  open access publication – free to read
  22. ^ Health Technology Assessment international (HTAi) (2015). "Good Practice Examples of Patient and Public Involvement in Health Technology Assessment (a living document)" (PDF). 
  23. ^ "Patient involvement in health technology assessment in Europe – results of the EPF survey" (PDF). European Patients Forum. 2013.  (Open Access)
  24. ^ Hailey, David; Werkö, Sophie; Bakri, Rugayah; Cameron, Alun; Göhlen, Britta; Myles, Susan; Pwu, Jasmine; Yothasamut, Jomkwan (2013). "Involvement of consumers in health technology assessment activities by INAHTA agencies". International Journal of Technology Assessment in Health Care. 29: 79–83. doi:10.1017/S026646231200075X. 
  25. ^ Facey, Karen (2011). "Patient involvement in HTA: What added value?". doi:10.3233/PPL-2011-0329.  (Open Access)
  26. ^ Gauvin, Francois-Pierre; Abelson, Julia; Giacomini, Mita; Eyles, John; Lavis, John N. (2010). "'It all depends': Conceptualizing public involvement in the context of health technology assessment agencies". Social Science & Medicine. 70: 1518–1526. doi:10.1016/j.socscimed.2010.01.036. 
  27. ^ Facey, Karen; Boivin, Antoine; Gracia, Javier; Hansen, Helle Ploug; Scalzo, Alessandra Lo; Mossman, Jean; Single, Ann (2010). "Patients' perspectives in health technology assessment: A route to robust evidence and fair deliberation". International Journal of Technology Assessment in Health Care. 26 (3): 334–340. doi:10.1017/s0266462310000395. ISSN 1471-6348. 
  28. ^ Webster, Andrew: Evaluation, governance and moves to a socially robust assessment of health technology, Working Paper 34, York, 2006, page 8,
  29. ^ "Values and Standards for Patient Involvement in HTA". 
  30. ^ Kelly, Michael P.; Heath, Kelly Iona; Howick, Jeremy; Greenhalgh, Trisha (2015). "The importance of values in evidence-based medicine". BMC Medical Ethics. 16: 16:69. doi:10.1186/s12910-015-0063-3.  (Open Access)
  31. ^ "European Patients' Academy (EUPATI) – Patient education!". EUPATI. 
  32. ^ Borup, Gitte; Friis Bach, Karin; Schmiegelow, Merete; Wallach-Kildemoes, Helle; Jannik Bjerrum, Ole; Westergaard, Niels (2015). "A Paradigm Shift Towards Patient Involvement in Medicines Development and Regulatory Science: Workshop Proceedings and Commentary (open access copy)". Therapeutic Innovation & Regulatory Science. 1–8: 304–311. doi:10.1177/2168479015622668. (Subscription required (help)). 
  33. ^ Borup et al. 2015, p. 5 & note 29.
  34. ^ European Medicines Agency, Stakeholders and Communication Division (2015). Draft Work plan for the European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) 2016 (PDF) (Report). 
  35. ^ "Session 553: Overview". Salzburg Global Seminar. 
  36. ^ Bovenkamp, H.M.; Trappenburg, M. J. (2009). "Reconsidering Patient Participation in Guideline Development". Health Care Anal. 17: 198–216. doi:10.1007/s10728-008-0099-3. 
  37. ^ Adonis, Tamara (2016). "Patient-driven research agenda setting in the Netherlands, A qualitative study from the perspective of patient organizations and umbrella patient organizations on patient-driven research agenda setting" (PDF). 
  38. ^ Caron-Flinterman, Johanna Francisca (2005). A New Voice in Science: Patient participation in decision-making on biomedical research (PDF) (dissertation). Amsterdam: Vrije Universiteit. 
  39. ^ Bélisle-Pipon, Jean-Christophe; Rouleau, Geneviève; Birko, Stanislav (2018). "Early-career researchers' views on ethical dimensions of patient engagement in research". BMC Medical Ethics. 19: 198–216. doi:10.1186/s12910-018-0260-y. 
  40. ^ Nilsen, Elin Strømme; Tinderholdt Myrhaug, Hilde; Oliver, Sandy; Oxman, Andrew D (2006). "Methods of consumer involvement in developing healthcare policy and research, clinical practice guidelines and patient information material". Cochrane Database of Systematic Reviews. 17 (3): CD004563. doi:10.1007/s10728-008-0099-3. 
  41. ^ Austvoll-Dahlgren, A; Johansen, M (2012). "Pasienten som medvirker og kunnskapshåndterer" [The patient as participant and knowledge manager]. Norsk Epidemiologi. 23 (2): 225–230. doi:10.5324/nje.v23i2.1649. 
  42. ^ Harrison, Natalie. "Regressing or progressing: what next for the doctor/ patient relationship? Open Access". The Lancet Respiratory Medicine, Vol. 6, No. 3. (28 February 2018), pp. 178-180. Retrieved 2018-02-28. 
  43. ^ "IBM and MIT partner on $240M AI lab". Healthcare Dive. Retrieved 2017-09-30. 
  44. ^ Marcus, Amy Dockser (2011-06-16). "Lessons From AIDS/HIV Advocacy Efforts". WSJ. Retrieved 2017-09-30. 
  45. ^ "Patient Centered Outcomes Research Institute Fee | Internal Revenue Service". www.irs.gov. Retrieved 2017-09-30. 
  46. ^ Desmond-Hellmann, Susan (11 April 2012). "Toward precision medicine: A new social contract?"Paid subscription required. Editorial. Science Translational Medicine. 4 (129): 129ed3. doi:10.1126/scitranslmed.3003473. 
  47. ^ Hood, Leroy; Friend, Stephen H. (March 2011). "Predictive, personalized, preventive, participatory (P4) cancer medicine"Paid subscription required. Nature Reviews Clinical Oncology. 8 (3): 184–187. doi:10.1038/nrclinonc.2010.227. PMID 21364692. 
  48. ^ Roberts, Sam (17 March 2017). "John W. Walsh, Who Fought for Cure for Lung Disease, Dies at 68". New York Times. 
  49. ^ a b c Van De Belt, Tom H; Engelen, Lucien JLPG; Berben, Sivera AA; Schoonhoven, Lisette (11 June 2010). "Definition of Health 2.0 and Medicine 2.0: A Systematic Review". Journal of Medical Internet Research. 12 (2): e18. doi:10.2196/jmir.1350. ISSN 1438-8871. PMC 2956229Freely accessible. PMID 20542857. 
  50. ^ Topol, Eric (2015). The Patient Will See You Now: The Future of Medicine is in Your Hands. Basic Books. ISBN 978-0465054749. 
  51. ^ Hughes, Benjamin; Joshi, Indra; Wareham, Jonathan (2008). "Health 2.0 and Medicine 2.0: Tensions and Controversies in the Field". Journal of Medical Internet Research. 10 (3): e23. doi:10.2196/jmir.1056. 
  52. ^ "Hello Health – EHR – Telemedicine". Hello Health. 16 February 2017. 
  53. ^ "Home - Health 2.0". Health 2.0. 
  54. ^ "Learn more about Electronic Health Record (EHR) adoption | Providers & Professionals | HealthIT.gov". www.healthit.gov. 
  55. ^ a b "Improving Patient Outcomes and Diagnostics with EHRs | Providers & Professionals | HealthIT.gov". www.healthit.gov. 
  56. ^ "Improve Care Coordination using Electronic Health Records | Providers & Professionals | HealthIT.gov". www.healthit.gov. 
  57. ^ "Improve Medical Practice Management with Electronic Health Records | Providers & Professionals | HealthIT.gov". www.healthit.gov. 
  58. ^ Wagner, Edward H; Groves, Trish (2002-10-26). "Care for chronic diseases". BMJ: British Medical Journal. 325 (7370): 913–914. doi:10.1136/bmj.325.7370.913. ISSN 0959-8138. PMC 1124427Freely accessible. PMID 12399321. 
  59. ^ a b c d Baysari, M. T.; Westbrook, J. I. (2015-08-13). "Mobile Applications for Patient-centered Care Coordination: A Review of Human Factors Methods Applied to their Design, Development, and Evaluation". Yearbook of Medical Informatics. 10 (1): 47–54. doi:10.15265/IY-2015-011. ISSN 0943-4747. PMC 4587034Freely accessible. PMID 26293851. 
  60. ^ Chan, Steven Richard; Torous, John; Hinton, Ladson; Yellowlees, Peter (2014-05-06). "Mobile Tele-Mental Health: Increasing Applications and a Move to Hybrid Models of Care". Healthcare. 2 (4): 220–233. doi:10.3390/healthcare2020220. ISSN 2227-9032. PMC 4934468Freely accessible. PMID 27429272. 
  61. ^ Lewis, Kristopher; Reicher, Murray A. (2016). "Web Applications for Patient Communication". Journal of the American College of Radiology. 13 (12): 1603–1607. doi:10.1016/j.jacr.2016.09.013. 
  62. ^ Vahdat, Shaghayegh; Hamzehgardeshi, Leila; Hessam, Somayeh; Hamzehgardeshi, Zeinab (January 2014). "Patient Involvement in Health Care Decision Making: A Review". Iranian Red Crescent Medical Journal. 16 (1). doi:10.5812/ircmj.12454. ISSN 2074-1804. PMC 3964421Freely accessible. PMID 24719703. 
  63. ^ Council, National Research (1969-12-31). The Social Impact of AIDS in the United States. doi:10.17226/1881. ISBN 9780309046282. 
  64. ^ Research, Center for Drug Evaluation and. "Prescription Drug User Fee Act (PDUFA) - Externally-led Patient-Focused Drug Development Meetings". www.fda.gov. Retrieved 2017-09-17. 
  65. ^ "European Medicines Agency" (PDF). www.ema.europa.eu. 23 October 2014. Retrieved September 16, 2017. 
  66. ^ Barello, Serena; Graffigna, Guendalina; Vegni, Elena (2012). "Patient Engagement as an Emerging Challenge for Healthcare Services: Mapping the Literature". Nursing Research and Practice. 2012: 1–7. doi:10.1155/2012/905934. ISSN 2090-1429. 
  67. ^ a b Domecq, Juan Pablo; Prutsky, Gabriela; Elraiyah, Tarig; Wang, Zhen; Nabhan, Mohammed; Shippee, Nathan; Brito, Juan Pablo; Boehmer, Kasey; Hasan, Rim (2014-02-26). "Patient engagement in research: a systematic review". BMC Health Services Research. 14: 89. doi:10.1186/1472-6963-14-89. ISSN 1472-6963. 
  68. ^ Smith, Sophia K.; Selig, Wendy; Harker, Matthew; Roberts, Jamie N.; Hesterlee, Sharon; Leventhal, David; Klein, Richard; Patrick-Lake, Bray; Abernethy, Amy P. (2015-10-14). "Patient Engagement Practices in Clinical Research among Patient Groups, Industry, and Academia in the United States: A Survey". PLoS ONE. 10 (10): e0140232. doi:10.1371/journal.pone.0140232. ISSN 1932-6203. PMC 4605726Freely accessible. PMID 26465328. 
  69. ^ Wiljer, David; Urowitz, Sara; Apatu, Emma; DeLenardo, Claudette; Eysenbach, Gunther; Harth, Tamara; Pai, Howard; Leonard, Kevin J (2008-10-31). "Patient Accessible Electronic Health Records: Exploring Recommendations for Successful Implementation Strategies". Journal of Medical Internet Research. 10 (4): e34. doi:10.2196/jmir.1061. ISSN 1438-8871. PMC 2629367Freely accessible. PMID 18974036. 
  70. ^ Trotter, Jeffrey P. (2002). "Patient Registries: A New Gold Standard for "Real World" Research". The Ochsner Journal. 4 (4): 211–214. ISSN 1524-5012. PMC 3400525Freely accessible. PMID 22826660. 
  71. ^ "Rare Diseases Clinical Research Network (RDCRN)". www.rarediseasesnetwork.org. Retrieved 2017-09-17. 
  72. ^ a b Elizabeth., Hernberg-Ståhl, (2013). Orphan drugs : understanding the rare disease market and its dynamics. Reljanović, Miroslav. Oxford: WP, Woodhead Publishing. ISBN 9781908818393. OCLC 867555228. 
  73. ^ TA Workman (2013). "Defining Patient Registries and Research Networks". Engaging Patients in Information Sharing and Data Collection: The Role of Patient-Powered Registries and Research Networks. Rockville MD: Agency for Healthcare Research and Quality. 
  74. ^ Goldacre, Ben; Gray, Jonathan (8 April 2016). "OpenTrials: towards a collaborative open database of all available information on all clinical trials". Trials. 17: 164. doi:10.1186/s13063-016-1290-8Freely accessible.  open access publication – free to read
  75. ^ Schork, Nicholas J. (29 April 2015). "Personalized medicine: Time for one-person trials". Nature. 520 (7549): 609–611. doi:10.1038/520609aFreely accessible. 
  76. ^ Wagner, Jennifer K.; Peltz-Rauchman, Cathryn; Rahm, Alanna K.; Johnson, Christine C. (2017). "Precision engagement: the PMI's success will depend on more than genomes and big data"Paid subscription required. Genetics in Medicine. 19 (6): 620–624. doi:10.1038/gim.2016.165. 
  77. ^ Carte, Jennifer Levin; Cubino, Jennifer (2016). "Call to Action: Breaking down Barriers for Patient Participation in Oncology Clinical Trials" (PDF). Journal of Precision Medicine. Kneed Media. 

Further reading[edit]

External links[edit]

  • ^ Originally an EU project, EUPATI started receiving new funding in February 2017 under the direction of EPF, an umbrella organisation with two-thirds public and one-third private funding that works with patients’ groups.